Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,008 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bivalent mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease.
Quan J, Markovinović A, Hracs L, Ma C, Panaccione R, Kaplan GG; STOP COVID-19 in IBD Research Group. Quan J, et al. Among authors: ma c. Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1074-1075. doi: 10.1016/S2468-1253(23)00310-2. Epub 2023 Oct 6. Lancet Gastroenterol Hepatol. 2023. PMID: 37813111 No abstract available.
Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.
Quan J, Ma C, Panaccione R, Hracs L, Sharifi N, Herauf M, Markovinović A, Coward S, Windsor JW, Caplan L, Ingram RJM, Charlton C, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group. Quan J, et al. Among authors: ma c. Lancet Gastroenterol Hepatol. 2022 Dec;7(12):1077-1079. doi: 10.1016/S2468-1253(22)00340-5. Epub 2022 Oct 26. Lancet Gastroenterol Hepatol. 2022. PMID: 36306801 Free PMC article. No abstract available.
Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease.
Markovinović A, Quan J, Herauf M, Hracs L, Windsor JW, Sharifi N, Coward S, Caplan L, Gorospe J, Ernest-Suarez K, Ma C, Panaccione R, Ingram RJM, Kanji JN, Tipples G, Holodinsky JK, Bernstein CN, Mahoney DJ, Bernatsky S, Benchimol EI, Kaplan GG; STOP COVID-19 in IBD Research Group; STOP COVID-19 in IBD Research Group. Markovinović A, et al. Among authors: ma c. Am J Gastroenterol. 2023 Sep 1;118(9):1693-1697. doi: 10.14309/ajg.0000000000002337. Epub 2023 Jun 22. Am J Gastroenterol. 2023. PMID: 37216598 Free PMC article.
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease.
Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N; Alimentiv Translational Research Consortium (ATRC). Verstockt B, et al. Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):433-446. doi: 10.1038/s41575-023-00768-1. Epub 2023 Apr 17. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37069321 Review.
Design of Clinical Trials for Mild to Moderate Ulcerative Colitis.
Sedano R, Jairath V, Ma C; IBD Trial Design Group. Sedano R, et al. Among authors: ma c. Gastroenterology. 2022 Apr;162(4):1005-1018. doi: 10.1053/j.gastro.2021.12.284. Epub 2022 Jan 6. Gastroenterology. 2022. PMID: 34998800 No abstract available.
An Expert Consensus to Standardize Assessment of Bowel Cleansing for Clinical Trials of Bowel Preparations for Crohn's Disease.
Maratt JK, Siegel CA, Barkun AN, Bouhnik Y, Bressler B, Calderwood AH, East JE, Fischer M, Grossmann J, Korzenik JR, Menees SB, Panes J, Rex DK, Sey MSL, Allio MK, Baker KA, Guizzetti L, Remillard J, Sedano R, Feagan BG, Ma C, Jairath V. Maratt JK, et al. Among authors: ma c. Dig Dis Sci. 2023 May;68(5):1718-1727. doi: 10.1007/s10620-022-07775-3. Epub 2022 Nov 27. Dig Dis Sci. 2023. PMID: 36436154
17,008 results
You have reached the last available page of results. Please see the User Guide for more information.